Preclinical models of childhood cancer for the development of targeted therapies

Raushan T. Kurmasheva, Peter J Houghton

Research output: Contribution to journalReview article

Abstract

Childhood cancer represents a diverse group of malignancies that overall constitute approximately one percent of human cancer. With current multimodality therapies comprising surgery, radiation therapy and intensive chemotherapy, about seventy percent of children are cured of disease, and the 5-year Event-Free survival is approaching 80%. However, gains from current cytotoxic therapies come with a severe cost to the health of survivors. These rare cancers present unique challenges to developing new therapies, in part because relatively few clinical trials can be undertaken. Hence, developing preclinical models that accurately predict responsiveness to new agents assumes an increased importance. Here we review recent advances in preclinical models for development of molecularly targeted therapies.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalDrug Discovery Today: Disease Models
Volume21
DOIs
StatePublished - Feb 3 2016

Fingerprint

Neoplasms
Therapeutics
Health Care Costs
Disease-Free Survival
Survivors
Radiotherapy
Clinical Trials
Drug Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Preclinical models of childhood cancer for the development of targeted therapies. / Kurmasheva, Raushan T.; Houghton, Peter J.

In: Drug Discovery Today: Disease Models, Vol. 21, 03.02.2016, p. 3-9.

Research output: Contribution to journalReview article

@article{dedb5c446e174054b45dd6f2e9513491,
title = "Preclinical models of childhood cancer for the development of targeted therapies",
abstract = "Childhood cancer represents a diverse group of malignancies that overall constitute approximately one percent of human cancer. With current multimodality therapies comprising surgery, radiation therapy and intensive chemotherapy, about seventy percent of children are cured of disease, and the 5-year Event-Free survival is approaching 80{\%}. However, gains from current cytotoxic therapies come with a severe cost to the health of survivors. These rare cancers present unique challenges to developing new therapies, in part because relatively few clinical trials can be undertaken. Hence, developing preclinical models that accurately predict responsiveness to new agents assumes an increased importance. Here we review recent advances in preclinical models for development of molecularly targeted therapies.",
author = "Kurmasheva, {Raushan T.} and Houghton, {Peter J}",
year = "2016",
month = "2",
day = "3",
doi = "10.1016/j.ddmod.2017.02.001",
language = "English (US)",
volume = "21",
pages = "3--9",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Preclinical models of childhood cancer for the development of targeted therapies

AU - Kurmasheva, Raushan T.

AU - Houghton, Peter J

PY - 2016/2/3

Y1 - 2016/2/3

N2 - Childhood cancer represents a diverse group of malignancies that overall constitute approximately one percent of human cancer. With current multimodality therapies comprising surgery, radiation therapy and intensive chemotherapy, about seventy percent of children are cured of disease, and the 5-year Event-Free survival is approaching 80%. However, gains from current cytotoxic therapies come with a severe cost to the health of survivors. These rare cancers present unique challenges to developing new therapies, in part because relatively few clinical trials can be undertaken. Hence, developing preclinical models that accurately predict responsiveness to new agents assumes an increased importance. Here we review recent advances in preclinical models for development of molecularly targeted therapies.

AB - Childhood cancer represents a diverse group of malignancies that overall constitute approximately one percent of human cancer. With current multimodality therapies comprising surgery, radiation therapy and intensive chemotherapy, about seventy percent of children are cured of disease, and the 5-year Event-Free survival is approaching 80%. However, gains from current cytotoxic therapies come with a severe cost to the health of survivors. These rare cancers present unique challenges to developing new therapies, in part because relatively few clinical trials can be undertaken. Hence, developing preclinical models that accurately predict responsiveness to new agents assumes an increased importance. Here we review recent advances in preclinical models for development of molecularly targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=85014081921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014081921&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2017.02.001

DO - 10.1016/j.ddmod.2017.02.001

M3 - Review article

AN - SCOPUS:85014081921

VL - 21

SP - 3

EP - 9

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

ER -